Publication | Open Access

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Pancreatic CancerModified FolfirinoxMedicinePharmacologyClinical TrialsPharmacotherapyMetastatic Pancreatic CancerCancer TreatmentOncologyRadiation OncologyPhase 1Health Sciences